Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Goes Virtual, Splitting Non-oncology Development Between Covance And Quintiles

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Takeda Pharmaceuticals has teamed with contract research organizations Covance and Quintiles to move toward a "fully virtual outsourcing model," the company announced Feb. 15

You may also be interested in...



Large Chinese CROs To Benefit From Continued Outsourcing Trend, CRO Surveys Say

As Big Pharma continues its restructuring initiatives to outsource services to lower-cost emerging markets, Chinese and U.S. contract research organizations with the largest footprints and broadest capabilities will benefit from the ongoing trend, according to two recently released surveys on the CRO industry

Large Chinese CROs To Benefit From Continued Outsourcing Trend, CRO Surveys Say

As Big Pharma continues its restructuring initiatives to outsource services to lower-cost emerging markets, Chinese and U.S. contract research organizations with the largest footprints and broadest capabilities will benefit from the ongoing trend, according to two recently released surveys on the CRO industry

China's Leading CROs Go On Shopping Spree To Become One-Stop Vendors

China's leading contract research organizations, Wuxi PharmaTech and ShangPharma, in a race to win over Big Pharma with integrated service platforms, announced separate deals Oct. 24 to expand into new strategic areas

Related Content

UsernamePublicRestriction

Register

SC077158

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel